Although several clinical studies have suggested that some of the acute exacerbations of chronic bronchitis may be produced by certain viruses, the precise role of these agents in the pathogenesis of progressive chronic respiratory disease has not yet been defined.`8 The prolonged and complex natural history of chronic respiratory disease in man has made it extremely difficult to assess the role of viruses in this disease by classical epidemiologic methods. The development of a model system for the viral induction of chronic respiratory disease in the small laboratory animal might eliminate some of these problems and would provide an experimental basis for assessing the possible role of viral infection in the initiation and progression of chronic respiratory disease in man.
Since many of the human respiratory viruses such as the adenoviruses, parainfluenza viruses, respiratory syncytial virus and the rhinoviruses produce either an inapparent infection or no infection at all in small laboratory animals, these animals have not been very useful in studies of the pathogenesis of viral respiratory infections caused by these agents.`7 Influenza virus, however, will produce an acute upper respiratory infection in the unanesthetized ferret. If the ferrets are given ether at the time of inoculation, the disease produced will become more severe with serial passage.8 The virus will then become adapted to the lungs and produce an extensive pneumonia which is often fatal. In addition, influenza virus can be adapted to produce a lethal pulmonary disease in mice.8' To date, experimental infection of small laboratory animals with these viruses has not been shown to induce chronic respiratory disease. This accumulated experience suggests that, with the possible exception of the influenza viruses, it is unlikely that the direct inoculation of small laboratory animals with human respiratory viruses will produce a suitable laboratory model of viral chronic respiratory disease.
A systematic study of indigenous animal viruses as possible causes of chronic respiratory disease in small laboratory animals has not been undertaken. There are many animal viruses that belong to the same virus groups as the human respiratory viruses and the use of these viruses for the induction of experimental viral chronic respiratory disease might overcome the * Associate Professor of Medicine and Medical Microbiology. limited host range of the human respiratory viruses. In addition, the intensive study of natural acute and chronic respiratory disease in small laboratory animals might provide additional agents for use in potential animal model systems.
For many years Nelson at the Rockefeller Institute has been interested in the etiology of chronic respiratory disease in the laboratory rat."0'l This disease has been known for many years and the pathology was accurately described by Hektoen in 1916.' Two main types of lesions were characteristic. The most common lesion consisted of areas of consolidation with nodule formation. The nodules correspond microscopically to bronchial dilation with exudate and fibrosis. The second type of lesion consisted of gelatinous reddish-gray or light gray areas on the surface of the lungs. These were associated with mucoid degeneration of exudate and connective tissue proliferation. The different lesions occurred together in the same lungs and in the same lobes. The affected rats had few clinical symptoms except for snuffling and nasal discharge. A recent postmortem study of over 1, 200 Wistar albino rats demonstrated the pathologic lesion of chronic bronchiectasis in 94 per cent of the animals at 18 months of age.'
The etiology of this disease remained a puzzle for many years. Streptobacillus moniliformis, which was originally thought to be the etiologic agent, was subsequently proved to be a secondary invader.' In 1937 both Klieneberger-Nobel and Nelson isolated mycoplasma from the lungs and bronchial exudate of affected animals.""l Nelson subsequently designated the specific chronic respiratory disease associated with mycoplasma as "infectious catarrh."' Mycoplasmas could not be recovered, however, from a separate special colony of rats that had been developed in the 1930's by Nelson even though these animals continued to show the pathologic lesions of chronic respiratory disease. In 1946 Nelson demonstrated that the infectious agent of this disease, which he designated "enzootic bronchiectasis" or "endemic pneumonia," was filterable, transmissable to mice and to special pathogen free rats, and could not be cultivated on artificial media. The infected mice and rats regularly showed pneumonitic lesions whereas control animals were free of pulmonary disease. Subsequently, Nelson demonstrated that this agent was present naturally in certain other mouse colonies but not in the animals used in the original transmission studies.
Nelson described this agent as filterable through a Berkefield V filter. It could not be cultivated in embryonated eggs.' The agent was stable when stored in dry ice. All attempts to demonstrate bacteria or mycoplasma in this material either by cultivation on artificial media or by staining failed.
Nelson concluded, therefore, that the etiologic agent of enzootic bronchiectasis was a virus.
Joshi, in 1965, reported further studies with the infectious agent of enzootic bronchiectasis or chronic murine pneumonia.'7 A cytopathic agent was isolated in rat embryo skin tissue culture incubated for five to six days at 370C. and then at 25°C. for two days. Using this method, 80 per cent of the lungs tested yielded a cytopathic agent. The agent was reisolated from germ-free rats infected with tissue culture material. No agent was isolated from control animals.
This agent was stable at -20°C., was inactivated at 30-60 minutes at 56°C. and was sensitive to chloroform or acetone. Electron micrographs showed the agent to be round with a diameter of approximately 110 Angstroms. The agent produced pulmonary lesions after 21 days following intranasal inoculation of ten day old mice or four week old germ-free rats. These lesions consisted of peribronchial lymphoid infiltration. Mycoplasma isolation was sporadic from both normal and affected animals but the tissue culture isolates were apparently not tested for mycoplasma. Joshi concluded that this transmissable agent fulfilled Koch's postulates and was the specific cause of enzootic bronchiectasis or endemic pneumonia. Although Joshi did not isolate any mycoplasma from the lung specimens, many of the properties of the agent, such as morphology, solvent sensitivity, and replication in tissue culture with cytopathic effect are also properties of mycoplasma.
Intensive attempts to propagate Joshi's agent on a variety of media under various conditions may yet yield a member of the mycoplasma species. If, however, Joshi's agent is indeed a true virus and is the etiologic agent of enzootic bronchiectasis in rats, this would provide a suitable animal model system of viral-induced chronic respiratory disease in a small laboratory animal.
Two viruses, first isolated from mice in the course of experiments designed to recover possible human respiratory pathogens, are also potential agents for use in a small animal model system for virus-induced chronic respiratory disease.
Pneumonia virus of mice (PVM) was first isolated by Horsfall in 1940 in an attempt to recover some of the nonbacterial agents responsible for human respiratory disease.'8 This agent could be isolated from apparently normal laboratory mice obtained from several different breeders when the lung tissues were serially passaged at 7 to 9 day intervals. Pulmonary consolidation was noted after the first or second passage and the disease produced was an interstitial pneumonitis. Although the gross lesions resembled those produced by influenza virus in mice, they were usually less severe.
Microscopically, the pneumonitis resembled that produced by influenza virus. The bronchi and blood vessels were surrounded by dense accumulations of mononuclear cells, the alveolar septa were thickened and contained exudate, and the alveoli contained fluid with a varying amount of mononuclear and red blood cells. The bronchi often contained a polymorphonuclear exudate. The bronchial epithelium was hyperplastic.
PVM virus is stable at -76°C. but is completely inactivated after 30 minutes at 560 C. It hemagglutinates mouse and hamster erythrocytes, is sensitive to ether and is thought to be an RNA virus. By Gradacol filtration the virus appears to have a diameter of 100 to 150 millimicrons.&' Electron microscopy of PVM particles demonstrates spheres or filaments, 80-120 mnt in diameter, with an outer spike-covered envelope. It has been suggested that this virus is a member of a third myxovirus subgroup. ' Subsequent studies of Horsfall and Curnen demonstrated the presence of neutralizing antibody to this virus in the sera of mice, rabbits, cotton rats, monkeys, hamsters, and guinea pigs.' Twenty-seven per cent of 165 human sera had neutralizing antibody to PVM but a survey of paired sera obtained from patients with a variety of acute respiratory syndromes failed to reveal any antibody rise to PVM. The ease of isolation of PVM from animals without apparent disease and the observation that nonspecific substances such as normal chick-embryo suspension could stimulate the formation of neutralizing antibody led Horsfall and his colleagues to conclude that PVM was a latent infection.
Recent experiments by Tennant and co-workers indicate that hemagglutination-inhibition (HI) antibody to PVM virus is found only in mice, hamsters, and rats.' No human HI antibody was detected. In addition, these workers failed to demonstrate latent virus infection in several mouse colonies with considerable, little, or no PVM HI antibody. In their studies, this virus was of low transmissability or infectivity and occurred as an acute focal enzootic. It is possible that some of the differences noted between these two groups may be due to strain differences, for these two investigations are separated by more than 25 years. Although PVM has been described as a latent infection of mice, there are no studies of possible chronic infections following the acute disease. In addition, there have been no long-range studies of the effects of an acute PVM infection. The available information, however, suggests that PVM infection in mice might prove to be a valuable model system for studying viral chronic pulmonary disease.
In the early 1950's, Sendai or HVJ virus, a paramyxovirus, was recovered in Japan from mice that had been inoculated with lung tissue obtained at autopsy from cases of fatal pneumonia in infants." Later studies demonstrated this virus to be indigenous to mice and there is, thus, doubt as to the human origin of Sendai virus.' Sendai virus, however, is clearly related serologically to hemadsorption type 2 virus and is classified as myxovirus parainfluenza type 1.`Antibodies to Sendai virus appear in human sera following infection with serologically related paramyxoviruses. Sendai virus has also been isolated from hamsters, swine, and rats.'
In Japan, Sendai virus appeared in mouse colonies as epizootics lasting 3-4 months but the virus could also be recovered easily from apparently healthy mice.' The virus spread actively between animals and hemagglutination-inhibition (HI) antibody appeared to protect the mice against infection with Sendai virus. In a transmission experiment, all of the dayold mice infected via the respiratory tract with Sendai virus grown in tissue culture died within 7 days after inoculation. Cage mate contacts died within 12 days. Four-week old mice were much less susceptible to the lethal effect of Sendai virus and 8-week old mice were unaffected clinically by the virus.
In affected animals, Sendai virus produced an interstitial pneumonia similar to that seen in mice with influenza virus except that the bronchiolar involvement was more prominent in the Sendai virus infected animals. ' Tennant has reported another epidemiological pattern of Sendai virus infection.' When germ-free mice were placed in contact with mice harboring Sendai virus, an enzootic infection was observed. Virus was first detected at 5 days and by 10 days 80 per cent of the mice yielded virus. By 30 days all the mice had HI antibody and did not shed virus. The infection was clinically inapparent and the presence of serum antibody was correlated with the cessation of virus shedding.
Although no latent or chronic Sendai virus infections in mice have been demonstrated conclusively, this virus-host system has certain attributes that suggests that it might be developed into a suitable small laboratory animal model system for virus-induced chronic respiratory disease. First, Sendai virus is very closely related to hemadsorption type 2 virus (parainfluenza 1 virus) which has been shown to be an important pathogen of acute respiratory disease in children and possibly to cause some acute respiratory disease in adults.`' In addition the parainfluenza viruses have been implicated by some investigators as a cause of acute exacerbations of chronic bronchitis in man.' Second, the parainfluenza viruses have been shown to infect man under both natural and artificial circumstances in the presence of serum antibody.`tm Although recent studies have demonstrated that nasal antibody will protect against artificial infection with these agents, there is epidemiologic evidence to suggest that natural reinfection with these agents occurs during adult life."l"m Third, the parainfluenza viruses have been demonstrated to produce a persistent defective infection in certain tissue culture systems.' Once this persistent infection is established nearly all of the cells are infected. The yield of infectious virus is usually low and may be nonexistent. Transmission of the infection takes place at cell divisions without the intervention of extracellular virus but the growth of these cells is unimpaired. The presence of viral antigens in these cells can be detected by fluorescent antibody techniques. Sendai virus has been demonstrated to produce such a defective infection in tissue culture. It is possible that the failure to detect chronic or latent infections with the parainfluenza viruses in either experimental animals or man may be related to their ability to produce a defective infection. If this were to occur in vivo, no infectious virus would be isolated although continued infection with the defective virus could play an important role in the pathogenesis of chronic respiratory disease either through disturbance of cellular physiology or through an altered or autoimmune response. The Sendai virus-mouse model system might provide a mechanism for investigating these hypotheses.
All of the agents discussed appear to have promise as potential small animal model systems for the study of virus-induced chronic respiratory disease. Much care will be required, however, in the development of such model systems because of the complex relationships among bacteria, mycoplasmas, rickettsiae and viruses in these animals. The use of germ-free or specific pathogen-free animals may be required. On the basis of the data presented, however, it seems reasonable to undertake the necessary experiments since the development of a small animal mode system for virusinduced chronic respiratory disease would further our understanding of the role of viral infections in the initiation and progression of chronic respiratory disease in man.
